Terminated PHASE1 INTERVENTIONAL 1-arm NCT00311558

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b for Solid Tumors, Lymphoma or Myeloma

Sponsor: National Cancer Institute (NCI)

Conditions Cancer

Interventions SSG & interferon recombinant interferon alfa-2b sodium stibogluconate

Updated 6 times since 2017 Last updated: Jan 24, 2018 Started: Oct 31, 2005 Primary completion: May 31, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Cancer trials with similar outcome

Browse all Cancer trials

Listed as NCT00311558, this PHASE1 trial focuses on Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
The Cleveland Clinic

Data source: The Cleveland Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States